Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 75 entries
Sorted by: Best Match Show Resources per page
Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study.

Nutrition and cancer

Hamilton-Reeves JM, Johnson CN, Hand LK, Bechtel MD, Robertson HL, Michel C, Metcalf M, Chalise P, Mahan NJ, Mirza M, Lee EK, Sullivan DK, Klemp JR, Befort CA, Parker WP, Gibbs HD, Demark-Wahnefried W, Thrasher JB.
PMID: 33295204
Nutr Cancer. 2021;73(11):2671-2686. doi: 10.1080/01635581.2020.1856890. Epub 2020 Dec 09.

BACKGROUND: Overweight men with prostate cancer are more likely to suffer from recurrence and death following prostatectomy compared with healthy weight men. This study tested the feasibility of delivering a comprehensive program to foster weight loss before and weight...

Cite
Hamilton-Reeves JM, Johnson CN, Hand LK, et al. Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study. Nutr Cancer. 2020;73(11):2671-2686doi: 10.1080/01635581.2020.1856890.
Hamilton-Reeves, J. M., Johnson, C. N., Hand, L. K., Bechtel, M. D., Robertson, H. L., Michel, C., Metcalf, M., Chalise, P., Mahan, N. J., Mirza, M., Lee, E. K., Sullivan, D. K., Klemp, J. R., Befort, C. A., Parker, W. P., Gibbs, H. D., Demark-Wahnefried, W., & Thrasher, J. B. (2021). Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study. Nutrition and cancer, 73(11), 2671-2686. https://doi.org/10.1080/01635581.2020.1856890
Hamilton-Reeves, Jill M, et al. "Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study." Nutrition and cancer vol. 73,11 (2021): 2671-2686. doi: https://doi.org/10.1080/01635581.2020.1856890
Hamilton-Reeves JM, Johnson CN, Hand LK, Bechtel MD, Robertson HL, Michel C, Metcalf M, Chalise P, Mahan NJ, Mirza M, Lee EK, Sullivan DK, Klemp JR, Befort CA, Parker WP, Gibbs HD, Demark-Wahnefried W, Thrasher JB. Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study. Nutr Cancer. 2021;73(11):2671-2686. doi: 10.1080/01635581.2020.1856890. Epub 2020 Dec 09. PMID: 33295204; PMCID: PMC8371995.
Copy Download .nbib Format: NLM
Tolerability and pharmacokinetics of oxaloacetate 100 mg capsules in Alzheimer's subjects.

BBA clinical

Swerdlow RH, Bothwell R, Hutfles L, Burns JM, Reed GA.
PMID: 27051598
BBA Clin. 2016 Mar 10;5:120-3. doi: 10.1016/j.bbacli.2016.03.005. eCollection 2016 Jun.

Bioenergetics and bioenergetic-related functions are altered in Alzheimer's disease (AD) subjects. These alterations represent therapeutic targets and provide an underlying rationale for modifying brain bioenergetics in AD-affected persons. Preclinical studies in cultured cells and mice found that administering oxaloacetate...

Cite
Swerdlow RH, Bothwell R, Hutfles L, et al. Tolerability and pharmacokinetics of oxaloacetate 100 mg capsules in Alzheimer's subjects. BBA Clin. 2016;5:120-3doi: 10.1016/j.bbacli.2016.03.005.
Swerdlow, R. H., Bothwell, R., Hutfles, L., Burns, J. M., & Reed, G. A. (2016). Tolerability and pharmacokinetics of oxaloacetate 100 mg capsules in Alzheimer's subjects. BBA clinical, 5120-3. https://doi.org/10.1016/j.bbacli.2016.03.005
Swerdlow, Russell H, et al. "Tolerability and pharmacokinetics of oxaloacetate 100 mg capsules in Alzheimer's subjects." BBA clinical vol. 5 (2016): 120-3. doi: https://doi.org/10.1016/j.bbacli.2016.03.005
Swerdlow RH, Bothwell R, Hutfles L, Burns JM, Reed GA. Tolerability and pharmacokinetics of oxaloacetate 100 mg capsules in Alzheimer's subjects. BBA Clin. 2016 Mar 10;5:120-3. doi: 10.1016/j.bbacli.2016.03.005. eCollection 2016 Jun. PMID: 27051598; PMCID: PMC4816034.
Copy Download .nbib Format: NLM
Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells.

Oncotarget

Do TV, Hirst J, Hyter S, Roby KF, Godwin AK.
PMID: 28881569
Oncotarget. 2017 Jul 05;8(31):50376-50392. doi: 10.18632/oncotarget.18970. eCollection 2017 Aug 01.

Ovarian cancer is usually diagnosed at late stages when cancer has spread beyond the ovary and patients ultimately succumb to the development of drug-resistant disease. There is an urgent and unmet need to develop therapeutic strategies that effectively treat...

Cite
Do TV, Hirst J, Hyter S, et al. Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells. Oncotarget. 2017;8(31):50376-50392doi: 10.18632/oncotarget.18970.
Do, T. V., Hirst, J., Hyter, S., Roby, K. F., & Godwin, A. K. (2017). Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells. Oncotarget, 8(31), 50376-50392. https://doi.org/10.18632/oncotarget.18970
Do, Thuy-Vy, et al. "Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells." Oncotarget vol. 8,31 (2017): 50376-50392. doi: https://doi.org/10.18632/oncotarget.18970
Do TV, Hirst J, Hyter S, Roby KF, Godwin AK. Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells. Oncotarget. 2017 Jul 05;8(31):50376-50392. doi: 10.18632/oncotarget.18970. eCollection 2017 Aug 01. PMID: 28881569; PMCID: PMC5584138.
Copy Download .nbib Format: NLM
Differences in Breast and Colorectal Cancer Screening Adherence Among Women Residing in Urban and Rural Communities in the United States.

JAMA network open

Shete S, Deng Y, Shannon J, Faseru B, Middleton D, Iachan R, Bernardo B, Balkrishnan R, Kim SJ, Huang B, Millar MM, Fuemmler B, Jensen JD, Mendoza JA, Hu J, Lazovich D, Robertson L, Demark-Wahnefried W, Paskett ED.
PMID: 34605915
JAMA Netw Open. 2021 Oct 01;4(10):e2128000. doi: 10.1001/jamanetworkopen.2021.28000.

IMPORTANCE: Screening for breast and colorectal cancer has resulted in reductions in mortality; however, questions remain regarding how these interventions are being diffused to all segments of the population. If an intervention is less amenable to diffusion, it could...

Cite
Shete S, Deng Y, Shannon J, et al. Differences in Breast and Colorectal Cancer Screening Adherence Among Women Residing in Urban and Rural Communities in the United States. JAMA Netw Open. 2021;4(10):e2128000doi: 10.1001/jamanetworkopen.2021.28000.
Shete, S., Deng, Y., Shannon, J., Faseru, B., Middleton, D., Iachan, R., Bernardo, B., Balkrishnan, R., Kim, S. J., Huang, B., Millar, M. M., Fuemmler, B., Jensen, J. D., Mendoza, J. A., Hu, J., Lazovich, D., Robertson, L., Demark-Wahnefried, W., Paskett, E. D. (2021). Differences in Breast and Colorectal Cancer Screening Adherence Among Women Residing in Urban and Rural Communities in the United States. JAMA network open, 4(10), e2128000. https://doi.org/10.1001/jamanetworkopen.2021.28000
Shete, Sanjay, et al. "Differences in Breast and Colorectal Cancer Screening Adherence Among Women Residing in Urban and Rural Communities in the United States." JAMA network open vol. 4,10 (2021): e2128000. doi: https://doi.org/10.1001/jamanetworkopen.2021.28000
Shete S, Deng Y, Shannon J, Faseru B, Middleton D, Iachan R, Bernardo B, Balkrishnan R, Kim SJ, Huang B, Millar MM, Fuemmler B, Jensen JD, Mendoza JA, Hu J, Lazovich D, Robertson L, Demark-Wahnefried W, Paskett ED. Differences in Breast and Colorectal Cancer Screening Adherence Among Women Residing in Urban and Rural Communities in the United States. JAMA Netw Open. 2021 Oct 01;4(10):e2128000. doi: 10.1001/jamanetworkopen.2021.28000. PMID: 34605915; PMCID: PMC8491105.
Copy Download .nbib Format: NLM
A Curated Cancer Clinical Outcomes Database (C3OD) for accelerating patient recruitment in cancer clinical trials.

JAMIA open

Mudaranthakam DP, Thompson J, Hu J, Pei D, Chintala SR, Park M, Fridley BL, Gajewski B, Koestler DC, Mayo MS.
PMID: 30474074
JAMIA Open. 2018 Oct;1(2):166-171. doi: 10.1093/jamiaopen/ooy023. Epub 2018 Jul 10.

Data used to determine patient eligibility for cancer clinical trials often come from disparate sources that are typically maintained by different groups within an institution, use differing technologies, and are stored in different formats. Collecting data and resolving inconsistencies...

Cite
Mudaranthakam DP, Thompson J, Hu J, et al. A Curated Cancer Clinical Outcomes Database (C3OD) for accelerating patient recruitment in cancer clinical trials. JAMIA Open. 2018;1(2):166-171doi: 10.1093/jamiaopen/ooy023.
Mudaranthakam, D. P., Thompson, J., Hu, J., Pei, D., Chintala, S. R., Park, M., Fridley, B. L., Gajewski, B., Koestler, D. C., & Mayo, M. S. (2018). A Curated Cancer Clinical Outcomes Database (C3OD) for accelerating patient recruitment in cancer clinical trials. JAMIA open, 1(2), 166-171. https://doi.org/10.1093/jamiaopen/ooy023
Mudaranthakam, Dinesh Pal, et al. "A Curated Cancer Clinical Outcomes Database (C3OD) for accelerating patient recruitment in cancer clinical trials." JAMIA open vol. 1,2 (2018): 166-171. doi: https://doi.org/10.1093/jamiaopen/ooy023
Mudaranthakam DP, Thompson J, Hu J, Pei D, Chintala SR, Park M, Fridley BL, Gajewski B, Koestler DC, Mayo MS. A Curated Cancer Clinical Outcomes Database (C3OD) for accelerating patient recruitment in cancer clinical trials. JAMIA Open. 2018 Oct;1(2):166-171. doi: 10.1093/jamiaopen/ooy023. Epub 2018 Jul 10. PMID: 30474074; PMCID: PMC6241508.
Copy Download .nbib Format: NLM
Perturbation of BRMS1 interactome reveals pathways that impact metastasis.

PloS one

Zimmermann RC, Sardiu ME, Manton CA, Miah MS, Banks CAS, Adams MK, Koestler DC, Hurst DR, Edmonds MD, Washburn MP, Welch DR.
PMID: 34788285
PLoS One. 2021 Nov 17;16(11):e0259128. doi: 10.1371/journal.pone.0259128. eCollection 2021.

Breast Cancer Metastasis Suppressor 1 (BRMS1) expression is associated with longer patient survival in multiple cancer types. Understanding BRMS1 functionality will provide insights into both mechanism of action and will enhance potential therapeutic development. In this study, we confirmed...

Cite
Zimmermann RC, Sardiu ME, Manton CA, et al. Perturbation of BRMS1 interactome reveals pathways that impact metastasis. PLoS One. 2021;16(11):e0259128doi: 10.1371/journal.pone.0259128.
Zimmermann, R. C., Sardiu, M. E., Manton, C. A., Miah, M. S., Banks, C. A. S., Adams, M. K., Koestler, D. C., Hurst, D. R., Edmonds, M. D., Washburn, M. P., & Welch, D. R. (2021). Perturbation of BRMS1 interactome reveals pathways that impact metastasis. PloS one, 16(11), e0259128. https://doi.org/10.1371/journal.pone.0259128
Zimmermann, Rosalyn C, et al. "Perturbation of BRMS1 interactome reveals pathways that impact metastasis." PloS one vol. 16,11 (2021): e0259128. doi: https://doi.org/10.1371/journal.pone.0259128
Zimmermann RC, Sardiu ME, Manton CA, Miah MS, Banks CAS, Adams MK, Koestler DC, Hurst DR, Edmonds MD, Washburn MP, Welch DR. Perturbation of BRMS1 interactome reveals pathways that impact metastasis. PLoS One. 2021 Nov 17;16(11):e0259128. doi: 10.1371/journal.pone.0259128. eCollection 2021. PMID: 34788285; PMCID: PMC8598058.
Copy Download .nbib Format: NLM
Progesterone promotes immunomodulation and tumor development in the murine mammary gland.

Journal for immunotherapy of cancer

Werner LR, Gibson KA, Goodman ML, Helm DE, Walter KR, Holloran SM, Trinca GM, Hastings RC, Yang HH, Hu Y, Wei J, Lei G, Yang XY, Madan R, Molinolo AA, Markiewicz MA, Chalise P, Axelrod ML, Balko JM, Hunter KW, Hartman ZC, Lange CA, Hagan CR.
PMID: 33958486
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-001710.

BACKGROUND: Clinical studies have linked usage of progestins (synthetic progesterone [P4]) to breast cancer risk. However, little is understood regarding the role of native P4, signaling through the progesterone receptor (PR), in breast tumor formation. Recently, we reported a...

Cite
Werner LR, Gibson KA, Goodman ML, et al. Progesterone promotes immunomodulation and tumor development in the murine mammary gland. J Immunother Cancer. 2021;9(5)doi: 10.1136/jitc-2020-001710.
Werner, L. R., Gibson, K. A., Goodman, M. L., Helm, D. E., Walter, K. R., Holloran, S. M., Trinca, G. M., Hastings, R. C., Yang, H. H., Hu, Y., Wei, J., Lei, G., Yang, X. Y., Madan, R., Molinolo, A. A., Markiewicz, M. A., Chalise, P., Axelrod, M. L., Balko, J. M., Hunter, K. W., Hartman, Z. C., Lange, C. A., & Hagan, C. R. (2021). Progesterone promotes immunomodulation and tumor development in the murine mammary gland. Journal for immunotherapy of cancer, 9(5), . https://doi.org/10.1136/jitc-2020-001710
Werner, Lauryn R, et al. "Progesterone promotes immunomodulation and tumor development in the murine mammary gland." Journal for immunotherapy of cancer vol. 9,5 (2021). doi: https://doi.org/10.1136/jitc-2020-001710
Werner LR, Gibson KA, Goodman ML, Helm DE, Walter KR, Holloran SM, Trinca GM, Hastings RC, Yang HH, Hu Y, Wei J, Lei G, Yang XY, Madan R, Molinolo AA, Markiewicz MA, Chalise P, Axelrod ML, Balko JM, Hunter KW, Hartman ZC, Lange CA, Hagan CR. Progesterone promotes immunomodulation and tumor development in the murine mammary gland. J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-001710. PMID: 33958486; PMCID: PMC8103939.
Copy Download .nbib Format: NLM
Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells.

Molecular cancer research : MCR

Kuravi S, Cheng J, Fangman G, Polireddy K, McCormick S, Lin TL, Singh AK, Abhyankar S, Ganguly S, Welch DR, Jensen RA, McGuirk JP, Balusu R.
PMID: 33514657
Mol Cancer Res. 2021 May;19(5):913-920. doi: 10.1158/1541-7786.MCR-20-0738. Epub 2021 Jan 29.

Anaplastic large cell lymphoma (ALCL) is an aggressive type of non-Hodgkin lymphoma. More than three-fourths of anaplastic lymphoma kinase (ALK)-positive ALCL cases express the

Cite
Kuravi S, Cheng J, Fangman G, et al. Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells. Mol Cancer Res. 2021;19(5):913-920doi: 10.1158/1541-7786.MCR-20-0738.
Kuravi, S., Cheng, J., Fangman, G., Polireddy, K., McCormick, S., Lin, T. L., Singh, A. K., Abhyankar, S., Ganguly, S., Welch, D. R., Jensen, R. A., McGuirk, J. P., & Balusu, R. (2021). Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells. Molecular cancer research : MCR, 19(5), 913-920. https://doi.org/10.1158/1541-7786.MCR-20-0738
Kuravi, Sudhakiranmayi, et al. "Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells." Molecular cancer research : MCR vol. 19,5 (2021): 913-920. doi: https://doi.org/10.1158/1541-7786.MCR-20-0738
Kuravi S, Cheng J, Fangman G, Polireddy K, McCormick S, Lin TL, Singh AK, Abhyankar S, Ganguly S, Welch DR, Jensen RA, McGuirk JP, Balusu R. Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells. Mol Cancer Res. 2021 May;19(5):913-920. doi: 10.1158/1541-7786.MCR-20-0738. Epub 2021 Jan 29. PMID: 33514657.
Copy Download .nbib Format: NLM
Bayesian Hierarchical Factor Analysis for Efficient Estimation across Race/Ethnicity.

Revista Colombiana de estadistica

Hu J, Clark L, Shi P, Staggs VS, Daley C, Gajewski B.
PMID: 34393301
Rev Colomb Estad. 2021 Jul;44(2):313-329. Epub 2021 Jul 12.

Patient reported outcomes are gaining more attention in patient-centered health outcomes research and quality of life studies as important indicators of clinical outcomes, especially for patients with chronic diseases. Factor analysis is ideal for measuring patient reported outcomes. If...

Cite
Hu J, Clark L, Shi P, et al. Bayesian Hierarchical Factor Analysis for Efficient Estimation across Race/Ethnicity. Rev Colomb Estad. 2021;44(2):313-329
Hu, J., Clark, L., Shi, P., Staggs, V. S., Daley, C., & Gajewski, B. (2021). Bayesian Hierarchical Factor Analysis for Efficient Estimation across Race/Ethnicity. Revista Colombiana de estadistica, 44(2), 313-329.
Hu, Jinxiang, et al. "Bayesian Hierarchical Factor Analysis for Efficient Estimation across Race/Ethnicity." Revista Colombiana de estadistica vol. 44,2 (2021): 313-329.
Hu J, Clark L, Shi P, Staggs VS, Daley C, Gajewski B. Bayesian Hierarchical Factor Analysis for Efficient Estimation across Race/Ethnicity. Rev Colomb Estad. 2021 Jul;44(2):313-329. Epub 2021 Jul 12. PMID: 34393301; PMCID: PMC8356675.
Copy Download .nbib Format: NLM
Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight-Loss Intervention Randomized to High-Dose ω-3 Fatty Acids versus Placebo.

Cancer prevention research (Philadelphia, Pa.)

Fabian CJ, Befort CA, Phillips TA, Nydegger JL, Kreutzjans AL, Powers KR, Metheny T, Klemp JR, Carlson SE, Sullivan DK, Zalles CM, Giles ED, Hursting SD, Hu J, Kimler BF.
PMID: 34244155
Cancer Prev Res (Phila). 2021 Sep;14(9):893-904. doi: 10.1158/1940-6207.CAPR-20-0656. Epub 2021 Jul 09.

The inflammation-resolving and insulin-sensitizing properties of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids have potential to augment effects of weight loss on breast cancer risk. In a feasibility study, 46 peri/postmenopausal women at increased risk for breast cancer with...

Cite
Fabian CJ, Befort CA, Phillips TA, et al. Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight-Loss Intervention Randomized to High-Dose ω-3 Fatty Acids versus Placebo. Cancer Prev Res (Phila). 2021;14(9):893-904doi: 10.1158/1940-6207.CAPR-20-0656.
Fabian, C. J., Befort, C. A., Phillips, T. A., Nydegger, J. L., Kreutzjans, A. L., Powers, K. R., Metheny, T., Klemp, J. R., Carlson, S. E., Sullivan, D. K., Zalles, C. M., Giles, E. D., Hursting, S. D., Hu, J., & Kimler, B. F. (2021). Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight-Loss Intervention Randomized to High-Dose ω-3 Fatty Acids versus Placebo. Cancer prevention research (Philadelphia, Pa.), 14(9), 893-904. https://doi.org/10.1158/1940-6207.CAPR-20-0656
Fabian, Carol J, et al. "Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight-Loss Intervention Randomized to High-Dose ω-3 Fatty Acids versus Placebo." Cancer prevention research (Philadelphia, Pa.) vol. 14,9 (2021): 893-904. doi: https://doi.org/10.1158/1940-6207.CAPR-20-0656
Fabian CJ, Befort CA, Phillips TA, Nydegger JL, Kreutzjans AL, Powers KR, Metheny T, Klemp JR, Carlson SE, Sullivan DK, Zalles CM, Giles ED, Hursting SD, Hu J, Kimler BF. Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight-Loss Intervention Randomized to High-Dose ω-3 Fatty Acids versus Placebo. Cancer Prev Res (Phila). 2021 Sep;14(9):893-904. doi: 10.1158/1940-6207.CAPR-20-0656. Epub 2021 Jul 09. PMID: 34244155; PMCID: PMC8416797.
Copy Download .nbib Format: NLM
Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study.

Nutrition and cancer

Hamilton-Reeves JM, Johnson CN, Hand LK, Bechtel MD, Robertson HL, Michel C, Metcalf M, Chalise P, Mahan NJ, Mirza M, Lee EK, Sullivan DK, Klemp JR, Befort CA, Parker WP, Gibbs HD, Demark-Wahnefried W, Thrasher JB.
PMID: 33295204
Nutr Cancer. 2021;73(11):2671-2686. doi: 10.1080/01635581.2020.1856890. Epub 2020 Dec 09.

BACKGROUND: Overweight men with prostate cancer are more likely to suffer from recurrence and death following prostatectomy compared with healthy weight men. This study tested the feasibility of delivering a comprehensive program to foster weight loss before and weight...

Cite
Hamilton-Reeves JM, Johnson CN, Hand LK, et al. Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study. Nutr Cancer. 2020;73(11):2671-2686doi: 10.1080/01635581.2020.1856890.
Hamilton-Reeves, J. M., Johnson, C. N., Hand, L. K., Bechtel, M. D., Robertson, H. L., Michel, C., Metcalf, M., Chalise, P., Mahan, N. J., Mirza, M., Lee, E. K., Sullivan, D. K., Klemp, J. R., Befort, C. A., Parker, W. P., Gibbs, H. D., Demark-Wahnefried, W., & Thrasher, J. B. (2021). Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study. Nutrition and cancer, 73(11), 2671-2686. https://doi.org/10.1080/01635581.2020.1856890
Hamilton-Reeves, Jill M, et al. "Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study." Nutrition and cancer vol. 73,11 (2021): 2671-2686. doi: https://doi.org/10.1080/01635581.2020.1856890
Hamilton-Reeves JM, Johnson CN, Hand LK, Bechtel MD, Robertson HL, Michel C, Metcalf M, Chalise P, Mahan NJ, Mirza M, Lee EK, Sullivan DK, Klemp JR, Befort CA, Parker WP, Gibbs HD, Demark-Wahnefried W, Thrasher JB. Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study. Nutr Cancer. 2021;73(11):2671-2686. doi: 10.1080/01635581.2020.1856890. Epub 2020 Dec 09. PMID: 33295204; PMCID: PMC8371995.
Copy Download .nbib Format: NLM
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Sharma P, Abramson VG, O'Dea A, Nye L, Mayer I, Pathak HB, Hoffmann M, Stecklein SR, Elia M, Lewis S, Scott J, De Jong JA, Wang YY, Yoder R, Schwensen K, Finke K, Heldstab J, LaFaver S, Williamson SK, Phadnis MA, Reed GA, Kimler BF, Khan QJ, Godwin AK.
PMID: 33602685
Clin Cancer Res. 2021 Jul 15;27(14):3896-3904. doi: 10.1158/1078-0432.CCR-20-4879. Epub 2021 Feb 18.

PATIENTS AND METHODS: Eligible patients had HER2-negative MBC with any number of prior chemotherapies. Phase I was 3+3 dose-escalation design with three dose levels of alpelisib (250, 300, and 350 mg) daily plus nab-paclitaxel 100 mg/mRESULTS: A total of...

Cite
Sharma P, Abramson VG, O'Dea A, et al. Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2021;27(14):3896-3904doi: 10.1158/1078-0432.CCR-20-4879.
Sharma, P., Abramson, V. G., O'Dea, A., Nye, L., Mayer, I., Pathak, H. B., Hoffmann, M., Stecklein, S. R., Elia, M., Lewis, S., Scott, J., De Jong, J. A., Wang, Y. Y., Yoder, R., Schwensen, K., Finke, K., Heldstab, J., LaFaver, S., Williamson, S. K., Phadnis, M. A., Reed, G. A., Kimler, B. F., Khan, Q. J., & Godwin, A. K. (2021). Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(14), 3896-3904. https://doi.org/10.1158/1078-0432.CCR-20-4879
Sharma, Priyanka, et al. "Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,14 (2021): 3896-3904. doi: https://doi.org/10.1158/1078-0432.CCR-20-4879
Sharma P, Abramson VG, O'Dea A, Nye L, Mayer I, Pathak HB, Hoffmann M, Stecklein SR, Elia M, Lewis S, Scott J, De Jong JA, Wang YY, Yoder R, Schwensen K, Finke K, Heldstab J, LaFaver S, Williamson SK, Phadnis MA, Reed GA, Kimler BF, Khan QJ, Godwin AK. Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2021 Jul 15;27(14):3896-3904. doi: 10.1158/1078-0432.CCR-20-4879. Epub 2021 Feb 18. PMID: 33602685; PMCID: PMC8282704.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 75 entries